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ABSTRACT
Background  A lack of biomarkers that identify patients 
at risk for severe osteoarthritis (OA) complicates 
development of disease-modifying OA drugs.
Objective  To determine whether inﬂ  ammatory genetic 
markers could stratify patients with knee OA into high and 
low risk for destructive disease.
Methods  Genotype associations with knee OA 
severity were assessed in two Caucasian populations. 
Fifteen single nucleotide polymorphisms (SNPs) in six 
inﬂ  ammatory genes were evaluated for association with 
radiographic severity and with synovial ﬂ  uid mediators in 
a subset of the patients.
Results  Interleukin 1 receptor antagonist (IL1RN) SNPs 
(rs419598, rs315952 and rs9005) predicted Kellgren–
Lawrence scores independently in each population. One 
IL1RN haplotype was associated with lower odds of 
radiographic severity (OR=0.15; 95% CI 0.065 to 0.349; 
p<0.0001), greater joint space width and lower synovial 
ﬂ  uid cytokine levels. Carriage of the IL1RN haplotype 
inﬂ  uenced the age relationship with severity.
Conclusion  IL1RN polymorphisms reproducibly 
contribute to disease severity in knee OA and may 
be useful biomarkers for patient selection in disease-
modifying OA drug trials.
INTRODUCTION
Osteoarthritis (OA) is characterised by progressive 
loss of joint articular cartilage and subchondral 
bone remodelling. Although OA is the greatest 
cause of disability and much of the population 
is susceptible, some patients remain relatively 
stable with minimal change in their symptoms 
over time. Other patients, however, progress to 
severe structural deterioration that often leads to 
disability and joint replacement. One challenge 
in both clinical management of OA and develop-
ment of disease-modifying drugs is the lack of 
imaging or biomarker tools that predict which 
patients with OA are more likely to progress to 
severe disease. Genetics explain substantial OA 
variance,1 but genetic associations with knee OA 
severity or progression have not been replicated. 
Inﬂ  ammatory mediators regulate breakdown of 
collagen, proteoglycans and bone that constitute 
the articular joint tissues and appear to be part 
of the destructive process in OA. We and oth-
ers have previously shown that an imbalance in 
interleukin 1 (IL1) and IL1 antagonists contrib-
ute to cartilage loss and increased inﬂ  ammatory 
mediators in OA.2
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Variations in several genes for proteins that regu-
late inﬂ  ammation, including interleukin-1α (IL1α), 
IL1β, IL1 receptor antagonist (IL1Ra), IL10, tumour 
necrosis factor α (TNFα) and oestrogen receptor-α 
(ESR1), have been associated with differential 
expression of inﬂ  ammatory mediators,3–5 and most 
of these gene variations have been associated with 
susceptibility to OA in various joints.6–10 In this 
study, we therefore evaluated whether polymor-
phisms in selected inﬂ  ammatory genes and genes 
that regulate inﬂ  ammation could stratify patients 
with knee OA into high and low risk for radio-
graphic severity in two independent populations.
PATIENTS AND METHODS
Patient populations
Two independent populations were recruited at 
New York University Hospital for Joint Diseases 
(NYUHJD) and from the Prediction of Osteoarthritis 
Progression (POP) study (Duke University Medical 
Center). Institutional review board approval of 
protocols and informed consent of patients for 
this study were obtained. All Caucasian patients 
in the NYUHJD and POP populations that met 
clinical symptomatic criteria (American College 
of Rheumatology) and radiographic criteria for 
OA (Kellgren–Lawrence (KL) grade >1) of at least 
one knee and were age ≥38 years were included. 
Patients with histories of corticosteroid use, bilat-
eral knee replacements, other forms of arthritis, 
cancer or other chronic diseases beyond hyperten-
sion or hypercholesterolaemia were excluded. POP 
included subjects with knee OA of KL grade 1–3 
in at least one knee and excluded subjects with 
bilateral knee KL=4 scores, since the primary goal 
of the POP study was to evaluate the risk factors 
for progression and to develop a predictive model. 
Patient demographics are shown in table 1. Patients 
underwent standardised ﬁ  xed-ﬂ  exion  postero-
anterior knee radiographs with a positioning frame 
(SynaFlexer; Synarc, San Francisco, California, 
USA). Radiographs were scored for KL grade (0–4), 
medial and lateral joint space width (JSW) at the 
midportion of the joint space via electronic callipers 
in the NYUHJD cohort, or minimal JSW with digi-
tal callipers (TESA ISO 9001) in the POP cohort.
Genotyping
Blood samples (5 ml) were collected (pyrogen-free 
heparinised tubes) for DNA extraction. Fifteen single 
nucleotide polymorphisms (SNPs) in six inﬂ  ammatory 
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response genes, including those for IL1α, IL1β, IL1Ra, TNFα, 
IL10, oestrogen receptor 1, were genotyped. SNPs genotyped 
(gene, rs number, frequent nucleotide>less frequent nucleotide, 
minor allele frequency) were IL1A(+4845), rs17561, G>T, 30.5%; 
IL1B(−511), rs16944, C>T, 33.4%; IL1B(−1464), rs1143623, G>C, 
32.8%; IL1B(−3737), rs4848306, C>T, 44.7%; IL1B(+3954), 
rs1143634, C>T, 24.2%; IL1B(+3877), rs1143633, A>G, 39.7%; 
IL1RN(+2018), rs419598, T>C, 27.3%; IL1RN, rs315952, C>T, 
25.8%; IL1RN, rs9005, G>A, 30.5%; IL10(−1082), rs1800896, 
A>G, 46.7%; IL10(−819), rs1800871, T>C, 17.3%; IL10(−592), 
rs1800872, A>C, 20.2%; TNFA(−308), rs1800629, A>G, 21.7%; 
ESR1_PvuII, rs2234693, T>C, 44.9%; ESR1_Xbal, rs9340799, 
A>G, 33.8%. Genotyping was accomplished (Interleukin Genetics 
Clinical Laboratory, Waltham, Massachusetts, USA; CLIA certi-
ﬁ  ed) by PCR targeting the sequence surrounding the SNPs stud-
ied. Multiplexed single-base extension reactions were performed. 
Genotypes were analysed (Beckman Coulter, Brea, California, 
USA; CEQ8800) and ﬁ  nal genotypes were scored by laboratory 
personnel blinded to all patient data.
Synovial ﬂ  uid analysis
Synovial ﬂ   uid (SF) samples were a required component of 
participation in the POP study, so SF samples were avail-
able from all subjects in the POP cohort. Fifty POP subjects 
met the entrance criteria for this study as described earlier; 
therefore, the SF samples represented no selection bias. Fluid 
samples were aspirated directly (n=36) or by lavage (n=14), 
corrected for dilution by the urea method11 and analysed 
blinded to the clinical information. Cytokines (pg/ml) were 
quantiﬁ  ed by multiplex bead assays (Bio-Plex; Bio-Rad, Life 
Science research, Hercules, California, USA). High-sensitivity 
C-reactive protein concentrations (mg/l) were measured using 
the UBI Magiwel Enzyme Immunoassay (United Biotech, 
Mountain View, California, USA; minimum detectable concen-
tration of 0.00035 mg/l, interassay variation ≤7.4%). Cartilage 
oligomeric matrix protein (COMP) was measured by sandwich 
ELISA with monoclonal antibodies 17C10 and 16F12 to human 
COMP (minimum detection 120 ng/ml, intra-assay and inter-
assay variation ≤5.8% and 8.7%, respectively). IL1ra was mea-
sured using the Quantikine Human IL1Ra Immunoassay from 
R&D Systems (Minneapolis, Minnesota, USA), with a mini-
mum detectable dose of 6.26 pg/ml.
Statistical methods
Primary analyses evaluated associations between genotypes and 
radiographic severity, as measured by KL scores. Patients with 
KL scores of 1, 2 were compared with those with scores of 3, 4. 
To determine whether results were potentially due to aberrant 
KL score distributions, a second analysis was performed compar-
ing KL1 with KL2–4 (results were unchanged). Genotype devia-
tion from Hardy–Weinberg equilibrium was tested (Pearson’s χ² 
test) in the control sample. Genotype associations with radio-
graphic severity were determined using χ² statistics or Fisher’s 
exact test, adjusted for non-genetic risk factors, age, body mass 
index (BMI) and gender, where appropriate, using multivariate 
logistic regression analysis. The effect of multiple comparisons 
was considered in the discovery population (NYUHJD) involv-
ing 15 SNPs. Comparisons of JSW between genotypes were 
made using non-parametric Wilcoxon test and a mixed model 
analysis of variance for correlated data to adjust for two knees 
in the same subject.
RESULTS
The NYUHJD population was analysed ﬁ  rst. Patients with more 
severe knee OA (KL 3, 4 vs 1, 2) were older (p=0.013) but did not 
differ by gender (p=0.96) or BMI (p=0.46). Subsequent analyses 
were age adjusted.
All SNPs were in Hardy–Weinberg equilibrium and were 
evaluated for association with radiographic severity. After 
adjustment for multiple comparisons, one SNP in the IL1Ra 
gene (IL1RN) was signiﬁ  cantly associated with decreased risk 
for severe OA and two other IL1RN SNPs showed the same 
protective trend (table 2). IL10 SNPs, also associated with radio-
graphic severity, were not signiﬁ  cant after adjustment for mul-
tiple comparisons. We then tested the Duke POP cohort for 
IL1RN gene variations, based on association with severity in 
the NYUHJD population. In the POP study, age, gender or BMI 
were not signiﬁ  cant inﬂ  uences, but two of three IL1RN SNPs 
were signiﬁ  cantly associated with knee OA severity (table 2). 
All other SNPs tested in the NYUHJD population were subse-
quently evaluated in the POP patients, and none was signiﬁ  cant 
(data not shown).
Since all signiﬁ  cant SNPs were in one gene, we evaluated 
haplotype effects on severity. Of nine possible haplotypes 
from three IL1RN SNPs, four had a frequency >1%, and one 
(rs419598/rs315952/rs9005=CTA) was associated with reduced 
risk for severity in both populations (table 2).
We then combined the two populations for further analy-
ses focusing on the IL1RN loci. In the combined dataset, age 
was associated with severity (p=0.0065) but gender and 
BMI were not. IL1RN SNPs and haplotypes were associated 
with decreased risk for severe disease by KL grade and JSW 
(table 3). The ﬁ  rst JSW analysis was knee based and included 
the smaller JSW for all knees (n=251 knees with complete data; 
126 patients from NYUHJD and Duke POP). JSW analyses were 
adjusted for age, gender and BMI, and the knee-based analy-
sis used a mixed model analysis of variance for intercorrelated 
data to adjust for two knees in the same subject. Two IL1RN 
SNPs were signiﬁ  cantly associated with greater mean JSW, as 
was the IL1RN CTA haplotype (mean JSW in patients carrying 
the CTA haplotype=3.99 mm±1.77, vs reference haplotypes=
3.14 mm+1.93; p=0.0008). In addition to the IL1RN genotype 
and haplotype effects observed for the signal knees, a similar 
IL1RN CTA haplotype effect was seen in the contralateral knees 
when analysed for KL scores of 3–4 (OR=0.065; 95% CI 0.0076 
to 0.55; p=0.0024) and JSW (p=0.008).
In a person-based analysis of signal knees only, all signal 
knees (n=126 with complete data) from NYUHJD and Duke, 
were classiﬁ  ed as to medial (n=95) or lateral-dominant (n=31) 
disease. The protective effect was apparent for medial knee 
OA (mean JSW in patients carrying the CTA haplotype=3.37 
mm±1.66, vs reference haplotypes =2.29 mm±1.73; p=0.0054). 
There were no signiﬁ   cant IL1RN genotype associations for 
the lateral compartment (mean JSW in patients carrying the 
Table 1 Patient  demographics
  NYUHJD POP study*
Number of patients 80 50
Age (mean±SD) 65.6±9.9 61.2±11.9
Gender (% female) 61.3 82
BMI (mean±SD) 26.4 + 3.7 31.1 + 6.3
Trauma history (%) 20 18
Hand involvement† (%) 53 58
*Duke University Medical Center; †by clinical examination.
BMI, body mass index; NYUHJD, New York University Hospital for 
Joint Diseases; POP, Prediction of Osteoarthritis Progression study.
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Table 2  Genotype association with radiographic severity of knee osteoarthritis (OA) in two populations
Gene rs Number Genotypes compared
NYUHJD population (n=80*) Duke POP study (n=50)
Kellgren–Lawrence score >2 
(odds ratio (CI))
Kellgren–Lawrence score >2 
(odds ratio (CI))
IL1A(+4845)  rs17561 GG vs GT/TT 1.26 (0.48 to 3.28); p=0.63
IL1B(−511)  rs16944 CC vs CT/TT 0.89 (0.32 to 2.47); p=0.82
IL1B(−1464) rs1143623 GG vs GC/CC 1.96 (0.75 to 5.11); p=0.17
IL1B(−3737)  rs4848306 CC vs CT/TT 1.25 (0.45 to 3.48); p=0.68
IL1B(+3954)  rs1143634 CC vs CT/TT 1.36 (0.53 to 3.47); p=0.52
IL1B(+3877)  rs1143633 GG vs GA/AA 1.12 (0.43 to 2.91); p=0.81
IL1RN(+2018) rs419598 TT vs CT/CC 0.49 (0.175 to 1.37); p=0.174 0.031 (0.004 to 0.27); p=0.0016†
IL1RN rs315952 CC/CT vs TT 0.46 (0.15 to 1.20); p=0.113 0.32 (0.090 to 1.00); p=0.071
IL1RN rs9005 GG vs GA/AA 0.25 (0.091 to 0.680); p=0.0067‡ 0.084 (0.02 to 0.343); p=0.0006†
IL1RN haplotype rs419598/rs315952/
rs9005
Haplotype C,T,A (1 or 2 copies) 
vs no copies
0.29 (0.09 to 0.93); p=0.037† 0.031 (0.004 to 0.270); p=0.0016†
TNFA(−308) rs1800629 GG vs GA/AA 1.37 (0.040 to 4.70); p=0.62
 
IL10(−1082)  rs1800896 CC vs CT/TT 3.00 (0.87 to 10.34); p=0.081
IL10(−819)  rs1800871 CC vs CT/TT 3.32 (1.08 to 10.28); p=0.037
IL10(−592) rs1800872 CC vs CA/AA 3.32 (1.08 to 10.28)§; p=0.037
ESR1_PvuII rs2234693 TT vs CT/CC 0.57 (0.22 to 1.49); p=0.25
ESR1_Xbal rs9340799 AA vs AG/GG 0.48 (0.18 to 1.25); p=0.13
Results in bold indicate signiﬁ  cant association with decreased risk for severe OA.
*Number of Caucasian patients with knee osteoarthritis who met inclusion criteria and had complete genotype data.
†IL1RN single nucleotide polymorphisms (SNPs) of interest from the NYUHJD population were then tested in the Duke POP population, and common haplotypes in the IL1RN gene were 
tested in both populations. p Values <0.05 were considered statistically signiﬁ  cant. All other SNPs tested in the NYUHJD population were subsequently evaluated in the POP patients, 
and none were signiﬁ  cant (data not shown).
‡For each single SNP, p values <0.027 were considered statistically signiﬁ  cant to account for multiple comparisons in the discovery population (NYUHJD) involving 15 SNPs.
§IL10(−819) and IL10(−592) alleles were completely concordant in this population.
NYUHJD, New York University Hospital for Joint Diseases; POP, Prediction of Osteoarthritis Progression study.
Table 3  Interleukin 1 receptor antagonist (IL1RN) genotype association with two radiographic parameters of severity in the combined populations
Genotype or haplotype
Frequency of indicated 
genotype or haplotype*
Kellgren–Lawrence score >2 
(odds ratio (CI))† (N=130)
Joint space width (JSW in mm)‡ (mean±SD)
Test genotype Reference genotype p Value§
IL1RN rs419598
CC/TC
0.35 0.22 (0.091 to 0.508); p=0.0005 3.83±1.91 (n=89) 3.19±1.88 (n=162) 0.036
IL1RN rs315952
TT
0.53 0.44 (0.21 to 0.92); p=0.0297 3.69±1.80 (n=132) 3.11±2.01 (n=117) 0.069
IL1RN rs9005
AA/GA
0.45 0.15 (0.065 to 0.349); p<0.0001 3.86±1.71 (n=114) 3.04±2.01 (n=135) 0.0063
IL1RN rs419598/ rs315952/rs9005
Carriage of Haplotype C,T,A
0.32 0.14 (0.053 to 0.368); p< 0.0001 3.99±1.77 (n=80) 3.14±1.93 (n=169) 0.0008
*Frequency within the total patients (n=130 with complete genetic data) with knee osteoarthritis (OA) from two separate populations (NYUHJD; Duke POP Study).
†Odds ratio for severe OA, as measured by Kellgren–Lawrence (KL) score, comparing the indicated genotype or haplotype with all other genotypes for that single nucleotide 
polymorphism. Patients were classiﬁ  ed by radiographic severity of knee OA by stratifying the KL scores to compare KL=1 or 2 vs KL=3 or 4. Similar signiﬁ  cant associations were 
found when patients were stratiﬁ  ed so that KL=1 was compared with KL=2–4 (data not shown).
‡The smaller JSW in millimetres for each knee was included in the knee-based analysis (n=251 knees with complete data in 126 patients from the NYUHJD and Duke POP 
populations). Statistical analysis was adjusted for age, gender and body mass index in a mixed model analysis of variance for intercorrelated data to adjust for the subject effect on two 
knees.
§Wilcoxon test.
NYUHJD, New York University Hospital for Joint Diseases; POP, Prediction of Osteoarthritis Progression study.
CTA haplotype=2.74 mm±2.21, vs reference haplotypes=2.23 
mm±1.67; p=0.53).
Since age has strong epidemiological associations with 
prevalence and severity of knee OA and was associated with 
severity in the combined studies, we evaluated the interac-
tion between age and IL1RN genotype relative to severity. In 
regression models, there was a signiﬁ  cant interaction between 
genotype and age (p<0.0001) relative to KL scores, with the 
effect of genotype being stronger at greater ages. The addi-
tion of the IL1RN haplotype to regression models that included 
age provided a better ﬁ  t than with age alone (p<0.0001). To 
examine the effect of genotype at different ages, we divided 
the population into age tertiles. Carriers of the CTA IL1RN 
haplotype were at signiﬁ  cantly lower risk for severe KL scores 
in each age group (  ﬁ  gure 1A). In regression models, age was 
associated with KL>2 in patients without the CTA haplotype 
(p=0.032) but not in those carrying the haplotype. Similarly, 
age was associated with JSW narrowing only in patients with 
knee OA who do not carry the CTA haplotype (ﬁ  gure 1B vs 
ﬁ  gure 1C).
Given that IL1RN alleles have been associated with different 
expression levels of inﬂ  ammatory mediators, we evaluated the 
inﬂ  uence of the IL1RN CTA haplotype on inﬂ  ammatory media-
tors in SF from the POP study (n=50). Patients carrying the 
IL1RN CTA haplotype had signiﬁ  cantly lower SF mean levels 
of IL10 (p=0.034), and showed a trend towards lower levels of 
IL1β and IL6 (table 4). No differences by IL1RN haplotype were 
seen for IL1Ra protein, monocyte chemotactic protein-1, mac-
rophage inﬂ  ammatory protein-1β, C-reactive protein or COMP 
(table 4). IL1Ra protein levels were positively correlated with 
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Figure 1  Inﬂ  uence of interleukin 1 receptor antagonist (IL1RN) haplotypes on the age relationship to severity of knee osteoarthritis (OA). (A) The 
ﬁ  gure stratiﬁ  es patients with knee OA into thirds by age (<59, n=42; 59–68, n=40; >68, n=47). The numbers in each group are not exactly equal 
owing to the distribution of patients at the intersection of the groups. Patients within each age group were then stratiﬁ  ed by carriage (dot-ﬁ  lled bars) 
or no carriage (grey-ﬁ  lled bars) of the IL1RN haplotype CTA of the single nucleotide polymorphisms (SNPs) rs419598/rs315952/rs9005. For each age 
strata and haplotype status, the frequency of severe radiographic knee OA (Kellgren–Lawrence (K–L) score >2) is plotted. (B, C) The joint space width 
(JSW) of each knee in patients with knee OA who do not (B) or do carry (C) the IL1RN CTA haplotype (rs419598/rs315952/rs9005) is plotted relative 
to age, and the regression line is shown for JSW relative to age. The JSW is signiﬁ  cantly associated with age (p=0.0059) in patients with knee OA 
who do not carry the IL1RN CTA haplotype, but not associated with age (p=0.56) in patients who carried one or two copies of the CTA haplotype.
IL6 levels both in patients without the CTA haplotype (p=0.002 
with exclusion of one outlier; mixed model considering two 
knees from an individual: p=0.04) and in patients with the CTA 
haplotype (p=0.029; mixed model: p=0.078). There was a pos-
itive correlation between levels of IL10 and IL1ra levels only 
in samples from patients without the IL1RN CTA haplotype 
(p=0.0048; mixed model: p=0.056). No association was seen 
between levels of IL10 and IL1ra levels in patients who carry 
the IL1RN CTA haplotype (p=0.37; mixed model: p=0.55) This 
effect appears to be due in part to the fact that in the lower 
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observed for genetic inﬂ  uence can presumably be attributed to 
the combination of genetic susceptibility and weight  bearing 
load (70% concentrated in the medial compartment) which 
together are necessary and sufﬁ  cient to cause OA preferentially 
in the medial compartment.
IL1 is well established as a regulator of cartilage degradation14 
and resorption of bone.12 We and others have previously shown 
that imbalances in IL1 and IL1 antagonists, such as the IL1Ra 
and the type II decoy receptor, contribute to cartilage loss and 
increased inﬂ  ammatory mediators in OA.2 Although blocking 
IL1 activity by intra-articular injections or by gene transfer of 
IL1Ra reduced cartilage and bone changes in animal models of 
OA,15 16 intra-articular IL1Ra injections in humans have pro-
duced mixed results for symptomatic knee OA.17
The IL1 gene cluster region has been repeatedly associated 
with susceptibility to OA in various joints, but the results have 
been inconsistent.7–9 18–20 An extended haplotype including 
SNPs in the IL1A, IL1B and IL1RN genes has been associated 
with increased susceptibility to OA in various joints,9 19 but that 
haplotype is not consistent with the IL1RN haplotypes that con-
tributed to knee OA severity in this study.
Of the three IL1RN SNPs associated with severity in this 
study, two (rs419598, exon 3 Ala/Ala; rs315952, exon 5, Ser/Ser) 
are in the coding regions of the IL1RN gene but do not change 
the amino acid sequence. The third, rs9005, is in the 3′-UTR of 
exon 4. Blood levels of IL1Ra have been associated with vari-
ous polymorphic loci within the IL1RN gene, but the ﬁ  ndings 
have been inconsistent. In two recent studies of more than 1000 
subjects,5 21 signiﬁ  cantly higher blood levels of IL1Ra protein 
were associated with allele T at one polymorphism (rs4251961) 
that is part of the broader haplotype marked by the CTA alleles 
included in this report. In addition, allele C at rs419598 of the 
CTA haplotype has been associated with increased peripheral 
blood mononuclear cell expression of IL1Ra and decreased risk 
for osteolysis after total hip arthroplasty.22
IL1β is among the ﬁ  rst genes activated with any tissue chal-
lenge, including biomechanical stress, and activates down-
stream cytokines including IL6 and IL10. The lower SF levels of 
IL10, IL1β and IL6 in the presence of the IL1RN CTA haplotype 
are consistent with lower IL1 biological activity, as would be 
expected in individuals with increased IL1Ra expression and a 
lower level of activation of local cytokine-producing cells.
Although no simple relationship was seen between the SF 
levels of IL1Ra and carriage of the IL1RN CTA haplotype in all 
patients, this relationship was evident in patients who were not 
in the highest tertile of IL10 levels. IL1Ra expression is directly 
activated by IL10 in both monocytes and neutrophils.23 24 The 
ﬁ  nding of a higher level of ILRa in SF samples from patients car-
rying the CTA haplotype only in the lower two tertiles of IL10 
protein is consistent with a genetic effect that may be evident 
only under submaximal activation conditions. For example, if 
one assumes near-maximal activation of IL1Ra when IL10 is 
strongly elevated, as would be expected in tertile 3 of IL10 lev-
els, a genotype effect on IL1ra expression may be less evident 
than at submaximal levels of IL10.
This study has potential limitations, including the moderate 
sample size, yet consistent and signiﬁ  cant severity associations 
with the IL1RN loci were found in two independently ascer-
tained populations. In addition, although the genotype asso-
ciation is with severity, longitudinal data are not available to 
assess actual disease progression rates. In this study, age was 
associated with radiographic severity, and although adjusted for 
in the statistical models, age may have had other confounding 
effects on the results. It should be emphasised that the IL1RN 
Table 4  Synovial ﬂ  uid inﬂ  ammatory mediators relative to carriage of 
interleukin 1 receptor antagonist (IL1RN) haplotypes
Synovial ﬂ  uid 
analyte
IL1RN haplotype 
(rs419598/rs315952/
rs9005=CTA) N* Mean† SD p Value‡
CRP (ng/ml) 0 28 5195.3 4991.4 0.74
1 or 2 copies 21 5160.4 4045.8
IL6 (pg/ml) 0 28 687.1 633.5 0.38
1 or 2 copies 19 430.2 437.4
IL10§ (pg/ml) 0 28 109.4 222.7 0.034
1 or 2 copies 19 13.4 42.7
IL1β§ (pg/ml) 0 28 3.46 8.38 0.40
1 or 2 copies 19 0.63 2.04
IL1Ra¶ (pg/ml) 0 16 483 334.6 0.72
1 or 2 copies   7 468.5 184.2
MCP (pg/ml) 0 29 763.7 389 0.49
1 or 2 copies 21 789.7 303.3
MIP (pg/ml) 0 29 380.9 233.4 0.91
1 or 2 copies 21 360.6 169.1
COMP (ng/ml) 0 29 35020 23280 0.52
  1 or 2 copies 21 30441 20677   
*Number of patients.
†The mean of the mediator values of the two knees was used to represent the mediator 
value for the patient.
‡Non-parametric Wilcoxon test.
§Values of these parameters that were below the lower limit of detection of the assay 
were assigned the value of 0.5 times the lower limit to facilitate data analysis. Fifty-
two per cent of the IL10 values and 82% of the IL1β values were below the detection 
threshold limit.
¶aIL1Ra analysis was performed at a later time than analysis of the other analytes and 
fewer samples remained available with sufﬁ  cient volume for analysis.
COMP, cartilage oligomeric matrix protein; IL1, interleukin 1; IL1Ra, interleukin 
1 receptor antagonist; MCP, monocyte chemotactic protein-1; MIP, macrophage 
inﬂ  ammatory protein-1β.
levels of IL10 (tertiles 1 and 2) IL1Ra is increased in CTA carriers, 
as shown by the enrichment of CTA haplotype carriers com-
pared with non-carriers in the highest quartile of IL1Ra (54.5% 
vs 16.7%; p=0.07).
DISCUSSION
Inﬂ  ammatory mediators are produced by articular joint tissues 
in OA and have been implicated in disease pathogenesis.2 12 Of 
15 SNPs in six inﬂ  ammatory genes, variations in the gene for 
IL1Ra were signiﬁ   cantly associated with severe radiographic 
knee OA in two independent populations. One IL1RN haplo-
type was associated with decreased risk for radiographic sever-
ity, greater JSW, lower levels of SF inﬂ  ammatory  mediators 
and reduction of the age inﬂ  uence on severity. Although both 
populations were modest in size, these ﬁ  ndings are unlikely 
to be false positives because (a) statistically signiﬁ  cant associa-
tions were observed for multiple SNPs in the same gene, IL1RN, 
whereas no associations were found for SNPs in other genes; (b) 
a speciﬁ  c IL1RN haplotype was protective in two independent 
populations and with two different severity parameters; (c) in 
the combined dataset, associations with severity were highly 
signiﬁ  cant (p<0.0001).
It is of interest that the IL1RN protective effect was only evi-
dent in the medial compartment. Although power to show a 
protective effect for lateral knee OA dominant disease was less, 
these ﬁ  ndings are consistent with previous reports of a stron-
ger genetic effect on medial disease. In a female twins study1 
changes over time in the medial compartment were clearly her-
itable but changes in the lateral compartment were not, and 
an MRI-based study13 also found a stronger genetic inﬂ  uence 
for medial cartilage loss. The differential compartment effects 
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haplotype that was associated with protection in late stages of a 
chronic disease that involves both bone and cartilage, may have 
a different or no effect on early disease initiation.
A substantial part of the variance in clinical expression of OA 
is attributed to genetics,1 and multiple SNPs have been associ-
ated with OA susceptibility.25 Few studies have evaluated the 
role of genetic factors in severity or progression of knee OA,26 27 
and, other than our report, we are not aware of genetic markers 
for knee OA severity validated in a second population.
The IL1RN CTA haplotype appears to identify a substantial 
segment of patients with knee OA who are at low risk for severe 
destruction, and the data suggest that IL1 biological activity is a 
determinant of knee OA severity. Biomarkers that identify patients 
more likely to develop severe disease should expedite successful 
development of disease-modifying OA drugs and improvements 
in medical and surgical management of knee OA.
Acknowledgements  We greatly appreciate the genotyping expertise provided 
by Kerry Chios, Julie Samia and Gary Breton, and input on data interpretation by Sir 
Gordon Duff.
Funding  This study was funded in part by the following grants: grant from Interleukin 
Genetics to NYUHJD; NIH grant: RO1 AR052873-01 to NYUHJD; NIH grant: U01 
AR050898 to Duke University.
Competing interests  When the research was conducted JFB, NA and KSK were full-
time employees and H-YW was a part-time consultant for Interleukin Genetics.
Patient consent Obtained.
Ethics approval  This study was conducted with the approval of the NYU 
institutional review board.
Contributors  The study concept, design was developed by SBA, KK, JB and 
MA. Data and statistical analysis was performed by NA, KK, VK and H-YH. Patient 
recruitment and clinical data collection were performed by SK, JS, JGB, GM and VK. 
The manuscript was drafted and critically checked by KK, NA, SA, VK and MA.
Provenance and peer review  Not commissioned; externally peer reviewed.
REFERENCES
 1.  Zhai G, Hart DJ, Kato BS, et al. Genetic inﬂ  uence on the progression of radiographic 
knee osteoarthritis: a longitudinal twin study. Osteoarthr Cartil 2007;15:222–5.
 2.  Attur MG, Dave M, Cipolletta C, et al. Reversal of autocrine and paracrine effects 
of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for 
pharmacological intervention. J Biol Chem 2000;275:40307–15.
 3.  Rogus J, Beck JD, Offenbacher S, et al. IL1B gene promoter haplotype pairs predict 
clinical levels of interleukin-1beta and C-reactive protein. Hum Genet 2008;123:387–98.
 4.  Kahraman S, Yilmaz R, Arici M, et al. IL-10 genotype predicts serum levels of 
adhesion molecules, inﬂ  ammation and atherosclerosis in hemodialysis patients. 
J Nephrol 2006;19:50–6.
 5.  Reiner AP, Wurfel MM, Lange LA, et al. Polymorphisms of the IL1-receptor 
antagonist gene (IL1RN) are associated with multiple markers of systemic 
inﬂ  ammation. Arterioscler Thromb Vasc Biol 2008;28:1407–12.
 6.  Valdes AM, Van Oene M, Hart DJ, et al. Reproducible genetic associations between 
candidate genes and clinical knee osteoarthritis in men and women. Arthritis Rheum 
2006;54:533–9.
 7.  Loughlin J, Dowling B, Mustafa Z, et al. Association of the interleukin-1 gene cluster 
on chromosome 2q13 with knee osteoarthritis. Arthritis Rheum 2002;46:1519–27.
 8.  Moos V, Rudwaleit M, Herzog V, et al. Association of genotypes affecting the 
expression of interleukin-1beta or interleukin-1 receptor antagonist with osteoarthritis. 
Arthritis Rheum 2000;43:2417–22.
 9.  Smith AJ, Keen LJ, Billingham MJ, et al. Extended haplotypes and linkage 
disequilibrium in the IL1R1-IL1A-IL1B-IL1RN gene cluster: association with knee 
osteoarthritis. Genes Immun 2004;5:451–60.
10.  Riyazi N, Kurreeman FA, Huizinga TW, et al. The role of interleukin 10 promoter 
polymorphisms in the susceptibility of distal interphalangeal osteoarthritis. 
J Rheumatol 2005;32:1571–5.
11.  Kraus VB, Huebner JL, Fink C, et al. Urea as a passive transport marker for arthritis 
biomarker studies. Arthritis Rheum 2002;46:420–7.
12.  Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inﬂ  ammatory 
disease: potential implication for the selection of new therapeutic targets. Arthritis 
Rheum 2001;44:1237–47.
13.  Zhai G, Ding C, Stankovich J, et al. The genetic contribution to longitudinal 
changes in knee structure and muscle strength: a sibpair study. Arthritis Rheum 
2005;52:2830–4.
14.  Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, 
MMP-13) genes in arthritis: integration of complex signaling pathways for the 
recruitment of gene-speciﬁ  c transcription factors. Arthritis Res 2002;4:157–64.
15.  Pelletier JP, Caron JP, Evans C, et al. In vivo suppression of early experimental 
osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 
1997;40:1012–19.
16.  Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of 
intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. 
Suppression of collagenase-1 expression. Arthritis Rheum 1996;39:1535–44.
17.  Chevalier X, Giraudeau B, Conrozier T, et al. Safety study of intraarticular injection 
of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a 
multicenter study. J Rheumatol 2005;32:1317–23.
18.  Kanoh T, Hasegawa Y, Masui T, et al. Interleukin-1beta gene polymorphism 
associated with radiographic signs of osteoarthritis of the knee. J Orthop Sci 
2008;13:97–100.
19.  Moxley G, Han J, Stern AG, et al. Potential inﬂ  uence of IL1B haplotype and 
IL1A-IL1B-IL1RN extended haplotype on hand osteoarthritis risk. Osteoarthr Cartil 
2007;15:1106–12.
20.  Moxley G, Meulenbelt I, Chapman K, et al. Interleukin-1 region meta-analysis with 
osteoarthritis phenotypes. Osteoarthr Cartil 2009;In Press.
21.  Raﬁ  q S, Stevens K, Hurst AJ, et al. Common genetic variation in the gene encoding 
interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA 
levels. Genes Immun 2007;8:344–51.
22.  Gordon A, Kiss-Toth E, Stockley I, et al. Polymorphisms in the interleukin-1 receptor 
antagonist and interleukin-6 genes affect risk of osteolysis in patients with total hip 
arthroplasty. Arthritis Rheum 2008;58:3157–65.
23.  Williams L, Jarai G, Smith A, et al. IL-10 expression proﬁ  ling in human monocytes. 
J Leukoc Biol 2002;72:800–9.
24.  Cassatella MA, Tamassia N, Crepaldi L, et al. Lipopolysaccharide primes neutrophils 
for a rapid response to IL-10. Eur J Immunol 2005;35:1877–85.
25.  Ryder JJ, Garrison K, Song F, et al. Genetic associations in peripheral joint 
osteoarthritis and spinal degenerative disease: a systematic review. Ann Rheum Dis 
2008;67:584–91.
26.  Valdes AM, Hart DJ, Jones KA, et al. Association study of candidate genes 
for the prevalence and progression of knee osteoarthritis. Arthritis Rheum 
2004;50:2497–507.
27.  Rego-Pérez I, Fernández-Moreno M, Fernández-López C, et al. Mitochondrial DNA 
haplogroups: role in the prevalence and severity of knee osteoarthritis. Arthritis Rheum 
2008;58:2387–96.
14_annrheumdis113043.indd   861 14_annrheumdis113043.indd   861 4/7/2010   3:54:03 PM 4/7/2010   3:54:03 PM